跳至主要内容
临床试验/NCT00385398
NCT00385398撤回2 期

Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer

University of Medicine and Dentistry of New Jersey0 个研究点开始时间: 2008年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
撤回
主要终点
Cognitive function

研究概览

简要总结

RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function (the ability to think, learn, remember, and judge) in patients with non-small cell lung cancer and brain metastases. A study that evaluates brain function may help doctors plan the best treatment.

PURPOSE: This phase II trial is studying the effect of radiosurgery, temozolomide, and erlotinib on brain function in patients with non-small cell lung cancer and brain metastases.

详细描述

OBJECTIVES:

Primary

  • Determine the effect of stereotactic radiosurgery, temozolomide, and erlotinib hydrochloride on cognitive function in patients with non-small cell lung cancer and brain metastases.

Secondary

  • Determine the feasibility and safety of this regimen, in terms of tumor response, time to tumor progression in brain, survival, physical functioning, and quality of life, in these patients.
  • Determine the frequency of O6-methylguanine-DNA methyltransferase promoter methylation in these patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Cognitive function

时间窗: 2 years

次要结局

  • Tumor response(2 years)
  • Time to tumor progression in brain(2 years)
  • Survival(2 years)
  • Quality of life as measured by FACT subscale(2 years)
  • Physical functioning as measured by Karnofsky performance status and Katz index of activities of daily living(2 years)
  • Frequency of O6-methylguanine-DNA methyltransferase promoter methylation(2 years)

研究者

申办方类型
Other
责任方
Sponsor

相似试验